+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Alzheimer's Disease Therapeutics Market 2024-2028

  • PDF Icon

    Report

  • 168 Pages
  • November 2023
  • Region: Global
  • TechNavio
  • ID: 5578851
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The alzheimer's disease therapeutics market is forecasted to grow by USD 5.41 billion during 2023-2028, accelerating at a CAGR of 10.03% during the forecast period. The report on the alzheimer's disease therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by availability, research, and development of novel biomarkers, increasing awareness of Alzheimers disease, and strong pipeline coupled with approval of therapeutics.

The alzheimer's disease therapeutics market is segmented as below:

By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • E-commerce pharmacy

By Drug Class

  • Cholinesterase inhibitors
  • N-methyl-D-aspartate receptor antagonist
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the emergence of regenerative therapies as one of the prime reasons driving the Alzheimer's disease therapeutics market growth during the next few years. Also, increasing funding for therapeutics discovery and availability of highly sensitive diagnostic modalities will lead to sizable demand in the market.

The report on the alzheimer's disease therapeutics market covers the following areas:

  • Alzheimer's disease therapeutics market sizing
  • Alzheimer's disease therapeutics market forecast
  • Alzheimer's disease therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alzheimer's disease therapeutics market vendors that include AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.. Also, the alzheimer's disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global alzheimers disease therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global alzheimers disease therapeutics market 2018 - 2022 ($ billion)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
4.3 Drug class Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Drug class Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Distribution Channel
6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Hospital pharmacy - Market size and forecast 2023-2028
Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
6.4 Retail pharmacy - Market size and forecast 2023-2028
Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
6.5 E-commerce pharmacy - Market size and forecast 2023-2028
Exhibit 42: Chart on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Distribution Channel
Exhibit 46: Market opportunity by Distribution Channel ($ billion)
Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)
7 Market Segmentation by Drug Class
7.1 Market segments
Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
7.2 Comparison by Drug Class
Exhibit 50: Chart on Comparison by Drug Class
Exhibit 51: Data Table on Comparison by Drug Class
7.3 Cholinesterase inhibitors - Market size and forecast 2023-2028
Exhibit 52: Chart on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
7.4 N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028
Exhibit 56: Chart on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
7.5 Others - Market size and forecast 2023-2028
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Drug Class
Exhibit 64: Market opportunity by Drug Class ($ billion)
Exhibit 65: Data Table on Market opportunity by Drug Class ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Canada - Market size and forecast 2023-2028
Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 Germany - Market size and forecast 2023-2028
Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 AB Science SA
Exhibit 115: AB Science SA - Overview
Exhibit 116: AB Science SA - Product / Service
Exhibit 117: AB Science SA - Key offerings
12.4 AbbVie Inc.
Exhibit 118: AbbVie Inc. - Overview
Exhibit 119: AbbVie Inc. - Product / Service
Exhibit 120: AbbVie Inc. - Key news
Exhibit 121: AbbVie Inc. - Key offerings
12.5 AgeneBio Inc.
Exhibit 122: AgeneBio Inc. - Overview
Exhibit 123: AgeneBio Inc. - Product / Service
Exhibit 124: AgeneBio Inc. - Key offerings
12.6 Aurobindo Pharma Ltd.
Exhibit 125: Aurobindo Pharma Ltd. - Overview
Exhibit 126: Aurobindo Pharma Ltd. - Product / Service
Exhibit 127: Aurobindo Pharma Ltd. - Key offerings
12.7 Cipla Ltd.
Exhibit 128: Cipla Ltd. - Overview
Exhibit 129: Cipla Ltd. - Business segments
Exhibit 130: Cipla Ltd. - Key news
Exhibit 131: Cipla Ltd. - Key offerings
Exhibit 132: Cipla Ltd. - Segment focus
12.8 Eisai Co. Ltd.
Exhibit 133: Eisai Co. Ltd. - Overview
Exhibit 134: Eisai Co. Ltd. - Business segments
Exhibit 135: Eisai Co. Ltd. - Key offerings
Exhibit 136: Eisai Co. Ltd. - Segment focus
12.9 Eli Lilly and Co.
Exhibit 137: Eli Lilly and Co. - Overview
Exhibit 138: Eli Lilly and Co. - Product / Service
Exhibit 139: Eli Lilly and Co. - Key news
Exhibit 140: Eli Lilly and Co. - Key offerings
12.10 Grifols SA
Exhibit 141: Grifols SA - Overview
Exhibit 142: Grifols SA - Business segments
Exhibit 143: Grifols SA - Key offerings
Exhibit 144: Grifols SA - Segment focus
12.11 H Lundbeck AS
Exhibit 145: H Lundbeck AS - Overview
Exhibit 146: H Lundbeck AS - Product / Service
Exhibit 147: H Lundbeck AS - Key offerings
12.12 Johnson and Johnson
Exhibit 148: Johnson and Johnson - Overview
Exhibit 149: Johnson and Johnson - Business segments
Exhibit 150: Johnson and Johnson - Key news
Exhibit 151: Johnson and Johnson - Key offerings
Exhibit 152: Johnson and Johnson - Segment focus
12.13 Lupin Ltd.
Exhibit 153: Lupin Ltd. - Overview
Exhibit 154: Lupin Ltd. - Product / Service
Exhibit 155: Lupin Ltd. - Key news
Exhibit 156: Lupin Ltd. - Key offerings
12.14 Novartis AG
Exhibit 157: Novartis AG - Overview
Exhibit 158: Novartis AG - Business segments
Exhibit 159: Novartis AG - Key offerings
Exhibit 160: Novartis AG - Segment focus
12.15 Pfizer Inc.
Exhibit 161: Pfizer Inc. - Overview
Exhibit 162: Pfizer Inc. - Product / Service
Exhibit 163: Pfizer Inc. - Key news
Exhibit 164: Pfizer Inc. - Key offerings
12.16 Solco Healthcare
Exhibit 165: Solco Healthcare - Overview
Exhibit 166: Solco Healthcare - Key offerings
12.17 Teva Pharmaceutical Industries Ltd.
Exhibit 167: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 168: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 170: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 171: Teva Pharmaceutical Industries Ltd. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 172: Inclusions checklist
Exhibit 173: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 174: Currency conversion rates for US$
13.4 Research methodology
Exhibit 175: Research methodology
Exhibit 176: Validation techniques employed for market sizing
Exhibit 177: Information sources
13.5 List of abbreviations
Exhibit 178: List of abbreviations
List of Exhibits
Exhibit 1: Executive Summary - Chart on Market Overview
Exhibit 2: Executive Summary - Data Table on Market Overview
Exhibit 3: Executive Summary - Chart on Global Market Characteristics
Exhibit 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 7: Executive Summary - Chart on Incremental Growth
Exhibit 8: Executive Summary - Data Table on Incremental Growth
Exhibit 9: Executive Summary - Chart on Vendor Market Positioning
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
Exhibit 12: Offerings of vendors included in the market definition
Exhibit 13: Market segments
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 18: Historic Market Size - Data Table on global alzheimers disease therapeutics market 2018 - 2022 ($ billion)
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
Exhibit 20: Historic Market Size - Drug class Segment 2018 - 2022 ($ billion)
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 42: Chart on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on E-commerce pharmacy - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on E-commerce pharmacy - Year-over-year growth 2023-2028 (%)
Exhibit 46: Market opportunity by Distribution Channel ($ billion)
Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)
Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibit 50: Chart on Comparison by Drug Class
Exhibit 51: Data Table on Comparison by Drug Class
Exhibit 52: Chart on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Cholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Cholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
Exhibit 56: Chart on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on N-methyl-D-aspartate receptor antagonist - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on N-methyl-D-aspartate receptor antagonist - Year-over-year growth 2023-2028 (%)
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibit 64: Market opportunity by Drug Class ($ billion)
Exhibit 65: Data Table on Market opportunity by Drug Class ($ billion)
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
Exhibit 111: Overview on factors of disruption
Exhibit 112: Impact of key risks on business
Exhibit 113: Vendors covered
Exhibit 114: Matrix on vendor position and classification
Exhibit 115: AB Science SA - Overview
Exhibit 116: AB Science SA - Product / Service
Exhibit 117: AB Science SA - Key offerings
Exhibit 118: AbbVie Inc. - Overview
Exhibit 119: AbbVie Inc. - Product / Service
Exhibit 120: AbbVie Inc. - Key news
Exhibit 121: AbbVie Inc. - Key offerings
Exhibit 122: AgeneBio Inc. - Overview
Exhibit 123: AgeneBio Inc. - Product / Service
Exhibit 124: AgeneBio Inc. - Key offerings
Exhibit 125: Aurobindo Pharma Ltd. - Overview
Exhibit 126: Aurobindo Pharma Ltd. - Product / Service
Exhibit 127: Aurobindo Pharma Ltd. - Key offerings
Exhibit 128: Cipla Ltd. - Overview
Exhibit 129: Cipla Ltd. - Business segments
Exhibit 130: Cipla Ltd. - Key news
Exhibit 131: Cipla Ltd. - Key offerings
Exhibit 132: Cipla Ltd. - Segment focus
Exhibit 133: Eisai Co. Ltd. - Overview
Exhibit 134: Eisai Co. Ltd. - Business segments
Exhibit 135: Eisai Co. Ltd. - Key offerings
Exhibit 136: Eisai Co. Ltd. - Segment focus
Exhibit 137: Eli Lilly and Co. - Overview
Exhibit 138: Eli Lilly and Co. - Product / Service
Exhibit 139: Eli Lilly and Co. - Key news
Exhibit 140: Eli Lilly and Co. - Key offerings
Exhibit 141: Grifols SA - Overview
Exhibit 142: Grifols SA - Business segments
Exhibit 143: Grifols SA - Key offerings
Exhibit 144: Grifols SA - Segment focus
Exhibit 145: H Lundbeck AS - Overview
Exhibit 146: H Lundbeck AS - Product / Service
Exhibit 147: H Lundbeck AS - Key offerings
Exhibit 148: Johnson and Johnson - Overview
Exhibit 149: Johnson and Johnson - Business segments
Exhibit 150: Johnson and Johnson - Key news
Exhibit 151: Johnson and Johnson - Key offerings
Exhibit 152: Johnson and Johnson - Segment focus
Exhibit 153: Lupin Ltd. - Overview
Exhibit 154: Lupin Ltd. - Product / Service
Exhibit 155: Lupin Ltd. - Key news
Exhibit 156: Lupin Ltd. - Key offerings
Exhibit 157: Novartis AG - Overview
Exhibit 158: Novartis AG - Business segments
Exhibit 159: Novartis AG - Key offerings
Exhibit 160: Novartis AG - Segment focus
Exhibit 161: Pfizer Inc. - Overview
Exhibit 162: Pfizer Inc. - Product / Service
Exhibit 163: Pfizer Inc. - Key news
Exhibit 164: Pfizer Inc. - Key offerings
Exhibit 165: Solco Healthcare - Overview
Exhibit 166: Solco Healthcare - Key offerings
Exhibit 167: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 168: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 170: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 171: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 172: Inclusions checklist
Exhibit 173: Exclusions checklist
Exhibit 174: Currency conversion rates for US$
Exhibit 175: Research methodology
Exhibit 176: Validation techniques employed for market sizing
Exhibit 177: Information sources
Exhibit 178: List of abbreviations

Executive Summary

The analyst recognizes the following companies as the key players in the global alzheimer's disease therapeutics market: AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is emergence of regenerative therapies.'

According to the report, one of the major drivers for this market is the availability, research, and development of novel biomarkers.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AB Science SA
  • AbbVie Inc.
  • AgeneBio Inc.
  • Biogen Inc.
  • Cipla Ltd.
  • Curasia Medilab
  • Denali Therapeutics Inc.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Grifols SA
  • H Lundbeck AS
  • Johnson and Johnson
  • Lifecare Neuro Products Ltd.
  • Lupin Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Psycogen Captab
  • Solco Healthcare
  • Teva Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.